EPSRC IRC Submission of Evidence to the Select Committee Inquiry into AMR&#xa0;

[[[EPSRC IRC Submission of Evidence to the House of Commons Science &amp; Technology ]]]

[[[Select Committee Inquiry into Antimicrobial Resistance ]]]6th November 2013.

[[[&#xa0;]]]

[[[1.0 ]]]

[[[Executive ]]]

[[[Summary]]] &#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;

[[[2.0 ]]]

[[[Who we are:]]]

[[[ ]]]We are a new EPSRC Interdisciplinary Research Collaboration (IRC) which aims to develop an Early Warning Sensing System for Infectious Diseases. The IRC brings together multidisciplinary teams of scientists, engineers and clinicians from UCL, Imperial College, the London School of Hygiene and Tropical Medicine, Newcastle University and Surrey University, together with NHS stakeholders, UCL Partners, Public Health England and industry partners.

[[[ ]]]We are pleased to make a short submission to the Select Committee’s inquiry into AMR1 and focus on the Committee’s questions regarding gaps in our knowledge of AMR and recommend prioritizing future research in next generation diagnostics and surveillance.&#xa0;

[[[3.0]]]&#xa0;&#xa0; 

[[[How has AMR developed in the past decade?]]]&#xa0;

[[[3.1]]]&#xa0;&#xa0; A key factor driving the development of AMR is the lack of rapid diagnostic and disease surveillance technologies to detect early-stage infections in community settings.1-6 The result is that worldwide many infections remain undiagnosed or are diagnosed at a late stage. This leads to on-going transmission by people unaware of their infections and widespread inappropriate use of antibiotics which fuels drug-resistance. Late diagnosis also limits our ability to respond to emerging AMR strains.&#xa0;

[[[3.2]]]&#xa0;&#xa0; Early detection plays a crucial role in all treatment and prevention strategies. However, current gold-standard diagnostic tests (e.g. RT-PCR and bacterial culture) are slow and require samples to be sent to specialist laboratories. This leads to inherent delays between tests, results and clinical interventions. Public health intervention may be further delayed by a time lag of 1-2 weeks, associated with retrospective surveillance of laboratory tests.&#xa0;

[[[3.3]]]&#xa0;&#xa0; There are national and international drivers to widen access to rapid tests at the point-of-care (PoC) but current tests (e.g. lateral flow tests) are typically not sensitive to early infections, leading to missed opportunities for interventions.6 &#xa0;

[[[3.4]]]&#xa0;&#xa0; Moreover while PoC tests may speed diagnosis, this data must be captured. If capability to capture information for national and international surveillance is lost, so too will our ability to respond to future threats. Therefore future rapid PoC tests must be sensitive to early infections and combined with data linkage. &#xa0;

[[[4.0]]]&#xa0;&#xa0; 

[[[Is there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection? If not how could this be rectified?]]]

[[[&#xa0;]]]

[[[4.1]]]&#xa0;&#xa0; In parallel with the development of new antimicrobials, there is a vital need for

[[[ ]]]new technologies to improve the early detection and diagnosis of infections, particularly in community settings. &#xa0;

[[[4.2]]]&#xa0;&#xa0; Research into new diagnostics has traditionally seen under-investment compared to treatment and vaccine programmes but there is a growing realisation that diagnostics are the gateway to informing correct treatment and prevention strategies. Better diagnostics will curb the inappropriate use of antibiotics, in turn preserving their effectiveness for future generations.

[[[&#xa0;]]]

[[[4.3]]]&#xa0;&#xa0; We welcome the Government’s recommendation to increase funding in this area but we note that there is no reference in the report to EPSRC research.1 There is a crucial need for core underpinning engineering and physical sciences research to fuel a pipeline of innovative 21st century diagnostic and surveillance technologies to prevent the spread of AMR. We recommend prioritising research in two key areas: (i) Web-tracking of infectious diseases across populations; (ii) Rapid Diagnostics with Data Linkage for Community Settings. 

[[[&#xa0;]]]

[[[4.4]]]&#xa0;&#xa0; 

[[[ ]]]

[[[Web-tracking of infectious diseases across populations ]]]&#xa0;4.41&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; The Government’s 5 Year AMR Strategy 2013-18 focuses on improving traditional surveillance systems.1 In addition, we recommend prioritising the use of web-information and crowd sourcing to improve early detection capabilities. &#xa0;4.42&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; Every week millions of people use the internet to search for information about health and self-report symptoms of an illness, often before they visit a doctor. For example, symptoms such as “fever”, “cough” or “diarrhoea” are investigated using search engines (e.g. Google or Bing), and posted on social networking and microblogging sites (e.g. Twitter). Although not everyone who types in symptoms is actually ill, a pattern emerges from trends in the total number of anonymised searches and tweets. &#xa0;4.43&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; Up-to-date estimates of outbreaks based on web-information linked to current epidemiological information may enable doctors to better respond to AMR. Web-information also has the advantage that it could potentially track infections across a much larger proportion of the population than current surveillance and might identify outbreaks even before people attend clinics. &#xa0;4.44&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; The low cost of these methods is likely to be of particular benefit in resource-limited settings such as developing countries, where infectious diseases are an enormous problem. &#xa0;4.45&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; Web information and crowd sourcing has been exploited for the identification of disease outbreaks, such as influenza, at an early stage. Similar tools could be applied to AMR, in combination with rapid diagnostics. Key examples of these technologies include: &#xa0;&#xa0;&#xa0;&#xa0;4.46&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; More research is needed to improve the evidence-base of these potentially highly valuable technologies and extend their use to AMR. Future research should target tools to improve their accuracy, geographical granularity and evaluate of their cost-effectiveness. &#xa0;4.47&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; We would like to highlight one of the key challenges facing the academic community in this area is restricted access to data, such as queries and tweets, held by private companies. New public-private partnerships, policy changes, governance frameworks are urgently required to responsibly develop this powerful resource for AMR, balancing the privacy of individuals with the benefits of research for the public good; &#xa0;4.48&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; Data linkage to current surveillance systems will also be crucial. &#xa0;4.49&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; Global coordination and action is urgently required since infectious diseases know no borders. More strategic alignment and investment is needed to support cross border activities and global networks of excellence. In particular, international web surveillance efforts could be significantly strengthened by a shared open-source software platform that provides the core software platform for national programs and allows national programs to focus on unique requirements, e.g. language.&#xa0;&#xa0;

[[[4.5]]]&#xa0;&#xa0; 

[[[R]]]

[[[apid Diagnostics with Data Linkage for ]]]

[[[C]]]

[[[ommunity Settings]]]:&#xa0;4.51&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; Rapid and accurate identification of the underlying agents using diagnostic tests is essential if we are to stop outbreaks with the correct control measures, for instance, containment, confinement, antimicrobials or vaccines. This is particularly true for emerging resistance, where we find ourselves in a race to develop new controls as the disease spreads. &#xa0;4.52&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; However current gold standard tests are laboratory-based and the inherent delays associated with sending sample off, obtaining test results and follow up appointments leads to delays in treatment and prevention strategies. &#xa0;4.53&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; The Government’s 5 Year AMR Strategy 2013-18, highlights the urgent need for the deployment of PoC diagnostics in community settings to speed diagnosis. However, robust, rapid, high-performance PoC technologies must first be developed to ensure this capability. This will require significant future research into, for example, new biomarkers which reduce the need for complex sample preparation steps, genomics, temperature-stable capture coatings, micro and nano-sensor systems with on-chip sample handling capabilities, low power microelectronics, big data analytics and data visualisation tools. 8-14 &#xa0;4.54&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; Increased availability of cost effective and easily deployable testing allows timely, more appropriate, and less costly treatment. It helps to rule out more expensive treatment and overtreatment, reduces the cost of treatment complications, and potentially reduces the length of stay in hospital. Moving early diagnosis into the community – particularly in settings such as residential homes, provides the opportunity for significant reductions in morbidity and mortality.&#xa0;4.55&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; As testing becomes more widespread in a variety of non-hospital settings, it will become vital to ensure information is captured for disease surveillance. Rapid diagnostic tests with data linkage, such as smartphone-connected tests, offer huge potential for rapid, real-time, geographically tagged diagnosis. This evidence can be combined with web-tracking efforts to map outbreaks at local, national and international levels to support early public health interventions. &#xa0;4.56&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; The enormous rise in mobile phones and internet usage in developed and developing countries presents an exciting opportunity to dramatically widen access to “smart diagnostics tests” to uncover and manage infection worldwide - for the common good. In 2013 the International Telecommunications Union estimates that there are 6.8 billion mobile subscriptions with rapid expansion in developing countries.14 Widening access to tests in community settings will empower patients to gain faster access to treatment, reduce the inappropriate use of antibiotics and protect the wider public.&#xa0;4.57&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; The rise in mobile health technologies is linked to a much larger trend in patients taking on much more interest and responsibility in their own health. For example, handheld glucose monitoring devices with data linkage to doctors are the standard of care for patients with diabetes. Mobile tests for AMR could also facilitate two-way interfaces, providing patients with advice on treatment (e.g. encouraging compliance to antibiotic treatment programmes) and relaying public information in the event of a serious outbreak. &#xa0;4.58&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; However there remain major scientific and technological challenges associated with the development of robust, high-performance tests for community settings. We see a need for major programmes of basic research at the interface between physical sciences, engineering, life sciences and medicine, to support technology translation, improve regulatory guidance and the health economic evaluation of new mobile health technologies. &#xa0;4.59&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; We also recommend creating AMR Fellowships, Grand Challenge research programmes, Centres for Doctoral Training and Global networks of excellence in AMR. Creating the tools, skill-sets, trained personnel and future leaders in AMR will ensure that the NHS is best placed to take advantage of emerging technologies to tackle AMR, and will also provide commercial opportunities for British industry.

[[[5.0]]]&#xa0;&#xa0; 

[[[References]]]&#xa0; 483 Year published:(2013);

[[[&#xa0;]]]

[[[&#xa0;]]]

[[[6.0]]] 

[[[Declaration of Interests: ]]]We are a new EPSRC Interdisciplinary Research Collaboration which aims to develop an Early Warning Sensing System for Infectious Diseases. For more information please contact the IRC Director, Professor Rachel McKendry (r.a.mckendry@ucl.ac.uk) and the Strategic Operations Director, Dr Tania Saxl (t.saxl@ucl.ac.uk). 2&#xa0;